BOSTON and LONDON, September 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a late-stage biotechnology company …
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
BOSTON and LONDON, September 19, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
Frequent IVI Complications
Frequent injections in the eye can cause infection, inflammation, and glaucoma. Akari is developing PAS-nomacopan with potential for 4 or fewer doses a year for …
Frequent IVI Burdens
Patients experience significant burdens (fear, discomfort, disruptions to their lives) with geographic atrophy (GA) treatments that are dosed monthly or every …
GA and Loss of Central Vision
Geographic atrophy (GA) is sight threatening. It causes loss of central vision, development of scotomas (blind spots), reduced reading speed and night vision …
